Liquid Biopsy is developing a new technology to detect and isolate rare tumor cells and has recently received EU funding.
Early diagnosis is one of the key factors in successful cancer treatment and the goal of this technology is to identify and analyze the rare cancer cells at an early stage. Christer Eriksson, Research Director at Liquid Biopsy, believes that a key to their successful grant application was the unique technology with a strong potential to meet important medical needs. This makes them an attractive collaboration partner.
